IQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says
IQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says is drawing significant interest across the industry.
IQVIA is well positioned to benefit from a projected rise in clinical trial activity through 2026, due to its large proprietary data assets, strong pharma relationships, and advantages in...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- PM Modi launches US firm’s chip unit in Gujarat: ‘Part of global supply chain’
- Radhika Merchant turns into a beautiful bridesmaid in rani pink lehenga for her friend's wedding in Jamnagar: Watch
- Like Reacher, Netflix’s Detective Hole Can Redeem Its Books’ Failed Movie
- Paper Bag Market to Reach US$ 9.6 Billion by 2032 Driven by Sustainability, Regulations, and Retail Expansion - Persistence Market Research
Source: Original →